Anesiva Inc

Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (September 2005)

39 slides from Anesiva's merger presentation, Sep 27, 2005

  1. Slide 1: Corgentech and AlgoRx Announce Merger Agreement

    Corgentech and AlgoRx Announce Merger Agreement Presentation to Corgentech Employees September 26, 2005

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “pla

  3. Slide 3: Forward Looking Statements (2)

    FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involv

  4. Slide 4: Creating Late-Stage Company

    CREATING LATE-STAGE COMPANY Multiple late-stage product development programs focused on significant clinical problems Pain management Inflammatory diseases Brings together development and commercial expertise in critical areas Marketing, commercialization, regulatory affairs and clinical trials mana

  5. Slide 5: Agenda

    AGENDA About AlgoRx Product Pipeline of Combined Company Terms and Timelines Communications Summary

  6. Slide 6: Corporate Background

    CORPORATE BACKGROUND Therapeutic Focus Three separate programs in pain management History Founded in March 2001 Raised $110.4MM Postponed IPO in February 2005 People ~21 employees Facilities Secaucus, NJ and Sunnyvale, CA

  7. Slide 7: Agenda

    AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary

  8. Slide 8: Product Pipeline

    PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALGRX 3268 Pre-procedural analgesia ALGRX 4975 Post-surgical pain Morton’s neuroma Tendonitis NF- B Decoy Atopic dermatitis (eczema) ALGRX 1207 Cutaneous neuropathic pain

  9. Slide 9: ALGRX 3268 - Topical Local Anesthesia

    ALGRX 3268- TOPICAL LOCAL ANESTHESIA Indication Reduction of pain associated with needlesticks for venipunctures and intravenous line placements Phase 3 trial underway Clinical data expected in second half of 2005 Key desirable product attributes Sterile, pre-filled, needle-free disposable delivery

  10. Slide 10: ALGRX 3268: Reduction in Pain from Venipuncture

    ALGRX 3268 Reduction in Pain from Venipuncture after Administration EMLA Package Insert for EMLA VAS, mm -10 -20 -30 Time after administration, minutes ALGRX 3268 VAS, mm -10 -20 -30 Time after administration, minutes ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a pretreatm

  11. Slide 11: ALGRX 3268 Development

    ALGRX 3268 DEVELOPMENT Total Protocol Age Group Phase Patients Primary Endpoint Status Primary Endpoint Antecubital Fossa Adults 1 272 Safety and Efficacy Achieved Primary Endpoint Back of Hand Adults 1 183 Safety and Efficacy Evaluate Circulating Achieved Primary Endpoint Pharmacokinetics Adults 1

  12. Slide 12: ALGRX 4975 - VR1 Anesthetic

    ALGRX 4975 – VR1 ANESTHETIC Capsaicin Overview Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does not affect other nerve fibers important for motor skills Activat

  13. Slide 13: ALGRX 4975 Development

    ALGRX 4975 DEVELOPMENT Total Protocol Phase Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery 2 40 Time to Rescue Medication Primary Endpoint Achieved Bunion Removal Surgery 2 182 Magnitude of Pain Relief Primary Endpoint Achieved Hernia Repair 2 48 Magnitude and Duration of

  14. Slide 14: Common, Chronic Problem

    COMMON, CHRONIC PROBLEM Eczema (Atopic Dermatitis) Red, cracked, and unbearably itchy skin caused by excess inflammation in the skin Makes the person more susceptible to infection 90% of people with AD have staph bacteria on their skin compared to <5% of people without AD Affects about 15 million pe

  15. Slide 15: Drug Comparison

    DRUG COMPARISON Topical NF- ?B Decoy Steroids Calcineurin Inhibitors Agents Efficacy +++ +++ ++ Twice a day Once a day or Once/twice a day Dosing Short-term/intermittent less Short-term long-term Skin-thinning None Limits use None Onset of +++ +++ ++ action Systemic May cause significant Black box w

  16. Slide 16: Phase 1/2's: Proof of Concept

    PHASE 1/2’s: PROOF OF CONCEPT Adults with mild-moderate eczema 200 cm2 affected area (treated area will be moderate) Randomized, double blind Endpoints Safety, tolerability and PK Multiple endpoints to assess preliminary efficacy Physician and patient assessments of target area (signs and symptoms)

  17. Slide 17: Phase 1/2's: Proof of Concept (2)

    PHASE 1/2’s: PROOF OF CONCEPT (2) US Trial 75 patients 9 sites Four cohorts (BID) 0.25% patients 0.50% 20 patients 1.00% 20 patients Placebo 15 patients Parallel dosing 21 days of treatment and 28 days of follow-up 57 enrolled patients Ex-US Trial 120 patients 9 sites (Switzerland and 8 in Australia

  18. Slide 18: ALGRX 1207

    ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: Neuropathic pain Dermatological surgery Surgical incisions

  19. Slide 19: ALGRX 1207

    ALGRX 1207 New local anesthetic allowing rapid and complete topical anesthesia without exotic delivery Percent complete anesthesia -120 -110 -100 -90 Percent complete anesthesia -120 -60 Time, minutes Time, minutes Lidocaine ALGRX 1207 Unique non-clinical results in relevant models

  20. Slide 20: Prevalence of Pain in Seven Major Countries

    PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES PATIENT NUMBERS (in thousands) Prevalence of post-operative pain 75,068 Prevalence of back pain 208,996 Prevalence of HIV and AIDS pain 847 Prevalence of diabetic neuropathy pain 13,243 Prevalence of osteoarthritic pain 46,610 Above indications are all tar

  21. Slide 21: 3268: Topical Local Anesthesia Market Dynamics

    3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric hospitals and specialized pediatric departments in larger general hospitals Continuing pressure on cost reduction and patient through-put in hos

  22. Slide 22: 3268: Needlestick/Venipuncture Marketplace in the U.S.

    3268: NEEDLESTICK/VENIPUNCTURE MARKETPLACE IN THE U.S. 42M Pediatric in-hospital 315M Adult in-hospital 40M Hemodialysis visits 54K Pediatric physician offices 11K Outpatient care centers1 1.3K Blood donation centers1 At home self-administration market 1. 2001 US census

  23. Slide 23: 3268: TLAs in Pediatric Hospital Settings

    3268: TLAs IN PEDIATRIC HOSPITAL SETTINGS Relevant Pediatric Procedures IV Insertions 27% Surgery/ IV Insertions 12% Spinal Tap/ LPs 12% Chemotherapy 1% Blood Draws 48% 18 million procedures* Treated Relevant Procedures IV Insertions 35% Surgery/ IV Insertions 19% Spinal Tap/ LPs 11% Chemotherapy 3%

  24. Slide 24: 3268: Current Clinical Practice of TLAs in Hospital Setting

    3268: CURRENT CLINICAL PRACTICE OF TLAs IN HOSPITAL SETTING Many hospitals offer TLA agents as an option to reduce needlestick pain Existence of established protocols for TLA use is mixed Nurses rather than physicians usually decision maker Some ERs apply TLAs, however use is often impractical due t

  25. Slide 25: 3268: Phased Marketing Approach

    3268: PHASED MARKETING APPROACH

  26. Slide 26: 4975: Post-Operative Pain Market

    4975: POST-OPERATIVE PAIN MARKET US post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively 50% indicate lack of adequate pain control Patients’ post-surgical pain experiences between 1993 and 1999 have not improved Europe also under treats post

  27. Slide 27: 4975: Potential Targets - High Volume Surgical Procedures

    4975: POTENTIAL TARGETS—HIGH VOLUME SURGICAL PROCEDURES Procedure Volume Caesarean Section 1,163,893 Hysterectomy (all) 1,042,715 Episiotomy 417,699 Arthroplasty (knee) 399,139 Hip Replacement, 343,554 total/partial CABG 316,471 Colorectal resection 280,969

  28. Slide 28: Current Post-Op Pain Medications vs. ALGRX 4975

    CURRENT POST-OP PAIN MEDICATIONS VS. ALGRX 4975 Epidurals Use declining significantly due to contra-indication in combination use with anticoagulants Opioids Nausea, vomiting, respiratory depression and constipation Sedation may limit the ability of the patient to ambulate and prolong time to discha

  29. Slide 29: NF-kB Decoy: Eczema Market

    NF-kB DECOY: ECZEMA MARKET Eczema market is comprised of mild, moderate and severe patient segments within the pediatric and adult patient populations Patient Population Segmented by Mild, Moderate and Severe (US, EU, Japan) Moderate 30% 15.6M Severe 10% 5.2M 31.1M Mild 60% Sources: 1. International

  30. Slide 30: NF-kB Decoy: Retail Rx Sales (U.S.)

    NF-kB DECOY: RETAIL Rx SALES (U.S.) Total Dollars (millions) $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 Corticosteroids Protopic Elidel Source: IMS Health, 2004

  31. Slide 31: 1207: Target Market

    1207: TARGET MARKET Deep, rapid penetration of the skin Long duration of action Addresses neuropathic pain market Non-exotic delivery Lidoderm® (Endo Pharmaceuticals) Postherpetic Neuralgia Indication ($ in millions) 2001 (IMS) $45 2002 (IMS) $107 2003 (IMS) $215 2004E (Endo) $300 2005E (Endo) $400

  32. Slide 32: Agenda

    AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary

  33. Slide 33: Terms of Merger Agreement

    TERMS OF MERGER AGREEMENT Both Secaucus and South San Francisco facilities to remain open Headquarters: South San Francisco Combined management team will work to integrate the companies and to identify synergies, redundancies and needs across the combined organization Corgentech and AlgoRx currently

  34. Slide 34: Projected Timetable

    PROJECTED TIMETABLE Sept 23 Execute merger agreement Sept 26 Analyst call pre-market open from AlgoRx AlgoRx employee meeting in mid-morning Fly to SF Corgentech employee meeting in mid-afternoon October and thereafter Investor and analyst meetings Week of Oct 17 File S-4 with SEC

  35. Slide 35: Projected Timetable (2)

    PROJECTED TIMETABLE (2) Week of Nov 14 First round of SEC comments File first amendment to S-4 Week of Nov 21* Second round of SEC comments File second amendment Week of Dec 5* Record date Week of Jan 2, 06* Shareholder special meetings * These dates assume that the SEC seeks additional review of ou

  36. Slide 36: Agenda

    AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary

  37. Slide 37: Communications

    COMMUNICATIONS Identify key individual contacts in Secaucus, Sunnyvale, and SSF to assure clear communication, answer questions, etc. during transition period Project teams Good venue to share information, discuss issues, solve problems, allocate resources Minutes within 36 hours – good means to upd

  38. Slide 38: Agenda

    AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary

  39. Slide 39: Strong Combined Company

    STRONG COMBINED COMPANY Increased development resources (personnel and financial) assure timely execution of multiple clinical trials Additional regulatory, manufacturing and quality resources assure timely FDA submissions, increased likelihood of successful plant inspections needed for FDA approval

Algorx Pharmaceuticals — Merger or Acquisition (September 2005) on 6ix